



**T R A N S F O R M**  
p h a r m a c e u t i c a l s , i n c .

For more information, please contact:

Barbara Carter  
TransForm Pharmaceuticals, Inc.  
(781)674-7834

Robert Stanislaro  
Euro RSCG Life NRP  
(212)845-4268

## **TRANSFORM PHARMACEUTICALS TO PRESENT AT TWO INDUSTRY CONFERENCES**

*Norman Selby, CEO and President, TransForm Pharmaceuticals will present at the 15<sup>th</sup> Annual Life Sciences Partnering Meeting and the UBS Warburg Global Life Sciences Investor Conference*

**Lexington, MA, September 15, 2003** – TransForm Pharmaceuticals, Inc., today announced that Norman Selby, CEO and President, will be presenting at the 15<sup>th</sup> Annual Life Sciences Partnering Meeting in San Francisco on Wednesday, September 17, 2003 and the UBS Warburg Global Life Sciences Investor Conference in New York City on Thursday, September 25, 2003.

Norman Selby will be presenting TransForm's business strategy, technology and key accomplishments at the following times and locations:

Event: **Burrill & Co. – The Life Sciences Partnering Meeting**  
Date: Wednesday, September 17, 2003  
Time: 9:00 a.m. (PT)  
Location: Four Seasons Hotel, San Francisco, California

Event: **UBS Warburg Global Life Sciences Investor Conference**  
Date: Thursday, September 25, 2003  
Time: 8:30 a.m. (ET)  
Location: The Plaza Hotel, New York City  
Audio: <http://www.ubswarburg.com>

(more)

The public is welcome to listen to UBS Warburg presentation through an audio webcast. To do so, please visit <http://www.ubswarburg.com> and click on the UBS Warburg conference link. Follow the link for live audio under the Global Life Sciences Conference heading. The Presentation will be available live and by replay.

### **About TransForm**

TransForm Pharmaceuticals is reinventing the pharmaceutical industry's approach to form and formulation, with a novel set of high-throughput, automated platform technologies, powered by state-of-the-art informatics and a scientific and managerial team with deep experience in pharmaceuticals. It uses these capabilities to optimize drug form and/or formulations, and increase the clinical and commercial value of pharmaceutical products, across the entire pharmaceutical value chain. In research and development, TransForm is working with partners such as Alza Corporation and Lilly, to help them make better candidate selection decisions, and reduce attrition and development time and cost. For later stage and marketed products, TransForm can help partners enhance product life cycle management by rapidly discovering novel forms and/or formulations to potentially improve bioavailability, broaden intellectual property protection and enable new dosage forms and/or combination products.

TransForm is also using these capabilities to develop its own proprietary product portfolio. TransForm, founded in late 1999 with initial technology from Millennium Pharmaceuticals (NASDAQ:MLNM), is a privately held company located in Lexington, MA. For more information visit our website at [www.transformpharma.com](http://www.transformpharma.com).

###